Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma: 18 cases (1992-2008)

Gillian Dank, Kenneth M. Rassnick, Orna Kristal, Carlos O. Rodriguez, Craig A. Clifford, Rebecca Ward, Courtney L. Mallett, Tracy Gieger, Gilad Segev

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

Objective-To determine outcome of dogs with presumed primary hepatic lymphomatreated with various multiagent, doxorubicin-based chemotherapeutic protocols and identifyfactors associated with prognosis.Design-Retrospective case series. Animals-18 dogs with presumed primary hepatic lymphoma.Procedures-Medical records were reviewed for information on signalment, treatment,and outcome.Results-8 dogs had a complete remission (CR), with a median remission duration of 120days. Dogs with leukocytosis, neutrophilia, hypoalbuminemia, hyperbilirubinemia, or acombination of hypoalbuminemia and hyperbilirubinemia were less likely to achieve a CR.Overall median survival time (MST) was 63 days (range, 2 to 402 days). In a multivariateanalysis, response to treatment and serum albumin concentration were associated withMST. Dogs that did not achieve a CR had a significantly shorter MST than did dogs thatdid achieve a CR (13 vs 283 days, respectively). Dogs with serum albumin concentration <2.5 g/dL at the time treatment was initiated had a significantly shorter MST than did dogswith serum albumin concentration within reference limits (10 vs 128 days, respectively).There was also a positive correlation between serum albumin concentration and survivaltime (r = 0.74).Conclusions and Clinical Relevance-Results suggested that dogs with primary hepaticlymphoma that underwent chemotherapy had a poor prognosis, with a low response rate.Dogs that responded to treatment had a better prognosis, and dogs with hypoalbuminemiahad a poorer prognosis.

Original languageEnglish (US)
Pages (from-to)966-971
Number of pages6
JournalJournal of the American Veterinary Medical Association
Volume239
Issue number7
DOIs
StatePublished - Oct 1 2011

Fingerprint

lymphoma
Lymphoma
Dogs
liver
dogs
Liver
remission
serum albumin
Serum Albumin
prognosis
hyperbilirubinemia
Hypoalbuminemia
Hyperbilirubinemia
doxorubicin
Leukocytosis
Doxorubicin
drug therapy
Medical Records
Therapeutics
Drug Therapy

ASJC Scopus subject areas

  • veterinary(all)

Cite this

Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma : 18 cases (1992-2008). / Dank, Gillian; Rassnick, Kenneth M.; Kristal, Orna; Rodriguez, Carlos O.; Clifford, Craig A.; Ward, Rebecca; Mallett, Courtney L.; Gieger, Tracy; Segev, Gilad.

In: Journal of the American Veterinary Medical Association, Vol. 239, No. 7, 01.10.2011, p. 966-971.

Research output: Contribution to journalArticle

Dank, G, Rassnick, KM, Kristal, O, Rodriguez, CO, Clifford, CA, Ward, R, Mallett, CL, Gieger, T & Segev, G 2011, 'Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma: 18 cases (1992-2008)', Journal of the American Veterinary Medical Association, vol. 239, no. 7, pp. 966-971. https://doi.org/10.2460/javma.239.7.966
Dank, Gillian ; Rassnick, Kenneth M. ; Kristal, Orna ; Rodriguez, Carlos O. ; Clifford, Craig A. ; Ward, Rebecca ; Mallett, Courtney L. ; Gieger, Tracy ; Segev, Gilad. / Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma : 18 cases (1992-2008). In: Journal of the American Veterinary Medical Association. 2011 ; Vol. 239, No. 7. pp. 966-971.
@article{828487d6b68c4362a9704c68dd073603,
title = "Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma: 18 cases (1992-2008)",
abstract = "Objective-To determine outcome of dogs with presumed primary hepatic lymphomatreated with various multiagent, doxorubicin-based chemotherapeutic protocols and identifyfactors associated with prognosis.Design-Retrospective case series. Animals-18 dogs with presumed primary hepatic lymphoma.Procedures-Medical records were reviewed for information on signalment, treatment,and outcome.Results-8 dogs had a complete remission (CR), with a median remission duration of 120days. Dogs with leukocytosis, neutrophilia, hypoalbuminemia, hyperbilirubinemia, or acombination of hypoalbuminemia and hyperbilirubinemia were less likely to achieve a CR.Overall median survival time (MST) was 63 days (range, 2 to 402 days). In a multivariateanalysis, response to treatment and serum albumin concentration were associated withMST. Dogs that did not achieve a CR had a significantly shorter MST than did dogs thatdid achieve a CR (13 vs 283 days, respectively). Dogs with serum albumin concentration <2.5 g/dL at the time treatment was initiated had a significantly shorter MST than did dogswith serum albumin concentration within reference limits (10 vs 128 days, respectively).There was also a positive correlation between serum albumin concentration and survivaltime (r = 0.74).Conclusions and Clinical Relevance-Results suggested that dogs with primary hepaticlymphoma that underwent chemotherapy had a poor prognosis, with a low response rate.Dogs that responded to treatment had a better prognosis, and dogs with hypoalbuminemiahad a poorer prognosis.",
author = "Gillian Dank and Rassnick, {Kenneth M.} and Orna Kristal and Rodriguez, {Carlos O.} and Clifford, {Craig A.} and Rebecca Ward and Mallett, {Courtney L.} and Tracy Gieger and Gilad Segev",
year = "2011",
month = "10",
day = "1",
doi = "10.2460/javma.239.7.966",
language = "English (US)",
volume = "239",
pages = "966--971",
journal = "Journal of the American Veterinary Medical Association",
issn = "0003-1488",
publisher = "American Veterinary Medical Association",
number = "7",

}

TY - JOUR

T1 - Clinical characteristics, treatment, and outcome of dogs with presumed primary hepatic lymphoma

T2 - 18 cases (1992-2008)

AU - Dank, Gillian

AU - Rassnick, Kenneth M.

AU - Kristal, Orna

AU - Rodriguez, Carlos O.

AU - Clifford, Craig A.

AU - Ward, Rebecca

AU - Mallett, Courtney L.

AU - Gieger, Tracy

AU - Segev, Gilad

PY - 2011/10/1

Y1 - 2011/10/1

N2 - Objective-To determine outcome of dogs with presumed primary hepatic lymphomatreated with various multiagent, doxorubicin-based chemotherapeutic protocols and identifyfactors associated with prognosis.Design-Retrospective case series. Animals-18 dogs with presumed primary hepatic lymphoma.Procedures-Medical records were reviewed for information on signalment, treatment,and outcome.Results-8 dogs had a complete remission (CR), with a median remission duration of 120days. Dogs with leukocytosis, neutrophilia, hypoalbuminemia, hyperbilirubinemia, or acombination of hypoalbuminemia and hyperbilirubinemia were less likely to achieve a CR.Overall median survival time (MST) was 63 days (range, 2 to 402 days). In a multivariateanalysis, response to treatment and serum albumin concentration were associated withMST. Dogs that did not achieve a CR had a significantly shorter MST than did dogs thatdid achieve a CR (13 vs 283 days, respectively). Dogs with serum albumin concentration <2.5 g/dL at the time treatment was initiated had a significantly shorter MST than did dogswith serum albumin concentration within reference limits (10 vs 128 days, respectively).There was also a positive correlation between serum albumin concentration and survivaltime (r = 0.74).Conclusions and Clinical Relevance-Results suggested that dogs with primary hepaticlymphoma that underwent chemotherapy had a poor prognosis, with a low response rate.Dogs that responded to treatment had a better prognosis, and dogs with hypoalbuminemiahad a poorer prognosis.

AB - Objective-To determine outcome of dogs with presumed primary hepatic lymphomatreated with various multiagent, doxorubicin-based chemotherapeutic protocols and identifyfactors associated with prognosis.Design-Retrospective case series. Animals-18 dogs with presumed primary hepatic lymphoma.Procedures-Medical records were reviewed for information on signalment, treatment,and outcome.Results-8 dogs had a complete remission (CR), with a median remission duration of 120days. Dogs with leukocytosis, neutrophilia, hypoalbuminemia, hyperbilirubinemia, or acombination of hypoalbuminemia and hyperbilirubinemia were less likely to achieve a CR.Overall median survival time (MST) was 63 days (range, 2 to 402 days). In a multivariateanalysis, response to treatment and serum albumin concentration were associated withMST. Dogs that did not achieve a CR had a significantly shorter MST than did dogs thatdid achieve a CR (13 vs 283 days, respectively). Dogs with serum albumin concentration <2.5 g/dL at the time treatment was initiated had a significantly shorter MST than did dogswith serum albumin concentration within reference limits (10 vs 128 days, respectively).There was also a positive correlation between serum albumin concentration and survivaltime (r = 0.74).Conclusions and Clinical Relevance-Results suggested that dogs with primary hepaticlymphoma that underwent chemotherapy had a poor prognosis, with a low response rate.Dogs that responded to treatment had a better prognosis, and dogs with hypoalbuminemiahad a poorer prognosis.

UR - http://www.scopus.com/inward/record.url?scp=80053638951&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=80053638951&partnerID=8YFLogxK

U2 - 10.2460/javma.239.7.966

DO - 10.2460/javma.239.7.966

M3 - Article

C2 - 21961637

AN - SCOPUS:80053638951

VL - 239

SP - 966

EP - 971

JO - Journal of the American Veterinary Medical Association

JF - Journal of the American Veterinary Medical Association

SN - 0003-1488

IS - 7

ER -